Eli Lilly and Company (LLY) reported Q3 non-GAAP earnings Thursday of $0.10 per diluted share, down from $1.98 a year earlier.
Analysts polled by Capital IQ expected $0.67.
Revenue for the quarter ended Sept. 30 was $9.50 billion, up from $6.94 billion a year earlier.
Analysts surveyed by Capital IQ expected $8.99 billion.
The company lowered 2023 guidance for non-GAAP earnings to $6.50 and $6.70 per share, from $9.70 to $9.90 previously. Analysts surveyed by Capital IQ expect $7.97. The drug maker also continues to expect revenue of $33.4 billion and $33.9 billion. Analysts surveyed by Capital IQ expect $33.42 billion.